Welm AL - Search Results

1

RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.

Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SAW. Dustin D, et al. Among authors: welm al. Br J Cancer. 2021 Jan;124(1):191-206. doi: 10.1038/s41416-020-01174-z. Epub 2020 Dec 1. Br J Cancer. 2021. PMID: 33257837 Free PMC article.

2

The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.

Kretschmann KL, Eyob H, Buys SS, Welm AL. Kretschmann KL, et al. Among authors: welm al. Curr Drug Targets. 2010 Sep;11(9):1157-68. doi: 10.2174/138945010792006825. Curr Drug Targets. 2010. PMID: 20545605 Review.

3

Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.

Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL. Liu X, et al. Among authors: welm al. Genes Cancer. 2011 Jul;2(7):753-62. doi: 10.1177/1947601911421924. Genes Cancer. 2011. PMID: 22207901 Free PMC article.

4

Mouse models of breast cancer metastasis to bone.

Kretschmann KL, Welm AL. Kretschmann KL, et al. Among authors: welm al. Cancer Metastasis Rev. 2012 Dec;31(3-4):579-83. doi: 10.1007/s10555-012-9378-4. Cancer Metastasis Rev. 2012. PMID: 22706780 Review.

5

Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Eyob H, et al. Among authors: welm al. Cancer Discov. 2013 Jul;3(7):751-60. doi: 10.1158/2159-8290.CD-12-0480. Epub 2013 Apr 23. Cancer Discov. 2013. PMID: 23612011 Free PMC article.

6

The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.

Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm AL. Cunha S, et al. Among authors: welm al. Cell Rep. 2014 Jan 16;6(1):141-54. doi: 10.1016/j.celrep.2013.12.010. Epub 2014 Jan 2. Cell Rep. 2014. PMID: 24388747 Free PMC article.

7

Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S. Sikora MJ, et al. Among authors: welm al. Cancer Res. 2014 Mar 1;74(5):1463-74. doi: 10.1158/0008-5472.CAN-13-2779. Epub 2014 Jan 14. Cancer Res. 2014. PMID: 24425047 Free PMC article.

8

Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL. Bieniasz M, et al. Among authors: welm al. Clin Cancer Res. 2015 Dec 15;21(24):5588-600. doi: 10.1158/1078-0432.CCR-14-3283. Epub 2015 Aug 19. Clin Cancer Res. 2015. PMID: 26289070 Free PMC article.

9

Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.

Giró-Perafita A, Palomeras S, Lum DH, Blancafort A, Viñas G, Oliveras G, Pérez-Bueno F, Sarrats A, Welm AL, Puig T. Giró-Perafita A, et al. Among authors: welm al. Clin Cancer Res. 2016 Sep 15;22(18):4687-97. doi: 10.1158/1078-0432.CCR-15-3133. Epub 2016 Apr 22. Clin Cancer Res. 2016. PMID: 27106068

10

Short-form Ron is a novel determinant of ovarian cancer initiation and progression.

Moxley KM, Wang L, Welm AL, Bieniasz M. Moxley KM, et al. Among authors: welm al. Genes Cancer. 2016 May;7(5-6):169-81. doi: 10.18632/genesandcancer.109. Genes Cancer. 2016. PMID: 27551332 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page